ESALF - Eisai: Margin Of Safety From Very Modest Penetration Expectations
2024-07-04 08:16:04 ET
Summary
- Eisai's story revolves around Leqembi and Lenvima, with Leqembi launching in Japan and expected to reach 10% of necessary revenue for fair value by end of year.
- Leqembi sales projected to hit 50 billion JPY by March 2025, contributing to fair value target of 572 billion JPY for Eisai.
- Assuming only 3.4% penetration in two years' time to get to fair value, assuming no foreign markets for Leqembi and no other revenues besides Lenvima.
- The margin of safety is quite apparent.
...
Eisai: Margin Of Safety From Very Modest Penetration Expectations